Open AccessOsimertinib therapy as first-line treatment before acquiring T790M mutation: from AURA1 trial
Author(s) -
Kentaro Ito,
Osamu Hataji
Publication year - 2018
Publication title -
journal of thoracic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 60
eISSN - 2077-6624
pISSN - 2072-1439
DOI - 10.21037/jtd.2018.07.52
Subject(s) - osimertinib , t790m , medicine , resistance mutation , mutation , oncology , acquired resistance , tyrosine kinase , first line , tyrosine kinase inhibitor , second line , clinical trial , cancer research , erlotinib , genetics , epidermal growth factor receptor , gefitinib , cancer , biology , gene , polymerase chain reaction , receptor , reverse transcriptase
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom